Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics IP Validation

27 Jul 2006 07:00

Angle PLC27 July 2006 For Immediate Release 27 July 2006 ANGLE plc ("ANGLE") Core intellectual property validation: Geomerics Ltd ("Geomerics") ANGLE, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce the validation ofProgeny(R) company Geomerics' core intellectual property through demonstrationof a revolutionary new computer graphics technology. Geomerics has unveiled technology that allows real-time radiosity in computergames utilising commodity graphics processing hardware. Radiosity, the processof fully modelling the subtle effects arising from the inter-reflections oflight between surfaces, dominates many real-world situations. Until now, sucheffects were considered beyond the reach of real-time techniques producingnoticeably 'unrealistic' lighting in computer games. Geomerics' breakthrough dynamic radiosity solution enables the full range oflighting effects, including inter-reflections, to be updated in real-time,providing significantly greater realism and impact. Geomerics has applied itscore intellectual property, based around geometric algebra, to produce thisradical new radiosity solution. The solution allows for fully dynamic lighting,including point spot-lights, area lights, texture-based lighting, glowingobjects and the projection of video onto geometry, all on common video hardware. Geomerics provided the first live demonstration of the technology at the DevelopConference in Brighton on 13 July. ANGLE is pleased to announce that subsequentindustry response to the technology was considerable, with over fifty commercialenquiries including many leading games developers. ANGLE believes that thisdemonstration is a validation of the power of Geomerics' core intellectualproperty and looks forward to both further applications and imminent commercialvalidation. Further details, including screenshots, movies, and previews of other Geomericssolutions can be found at www.geomerics.com Chris Doran, CEO and founder of Geomerics commented, "This revolutionarylighting technique is a demonstration of the potential of Geomerics' technologyand our unique approach to games middleware and technology licensing. Geometricalgebra provides opportunities for totally new solutions in a huge range ofgames problems, from lighting to physics and beyond." Andrew Newland, CEO of ANGLE, commented, "We are excited to view the validationof Geomerics' core intellectual property. The company has made good progress todate and we look forward to further applications of the core intellectualproperty in the near future." Geomerics, founded by ANGLE in 2005, is commercialising geometric algebratechnology developed at the University of Cambridge, UK, and in the USA. Thistechnology has applicability in the computer games industry, where it enablesfilm-quality visuals to be generated in real-time; in electromagnetic modelling,where a step-change in accuracy and speed can be seen; and in a wide selectionof other industries, to be announced by the company in due course. Geomerics is an ANGLE Progeny(R) Company. For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures GeomericsAlison Beasley of Lincoln Beasley PR +44 1608 645756 Buchanan CommunicationsRichard Darby, Amy Rajendran +44 207 466 5000 Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.